A - Agilent Technologies, Inc.
NYSE
->
Healthcare
->
Diagnostics & Research
Santa Clara,
United States
Type: Equity
A price evolution
A
| (in millions $) | 31 Aug 2024 | 30 May 2024 | 2 Mar 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $1779 | $1671 | $1748 | |
| Short term investments | ||||
| Net receivables | $1227 | $1249 | $1295 | $1291 |
| Inventory | $978 | $1000 | $1033 | $1031 |
| Total current assets | $4256 | $4203 | $4338 | $4186 |
| Long term investments | $186 | $177 | $170 | |
| Property, plant & equipment | $1446 | $1371 | $1314 | $1424 |
| Goodwill & intangible assets | $4357 | $4380 | $4410 | |
| Total noncurrent assets | $6740 | $6653 | $6610 | |
| Total investments | $186 | $177 | $170 | |
| Total assets | $10996 | $10856 | $10948 | $10763 |
| Current liabilities | ||||
| Accounts payable | $497 | $461 | $488 | $418 |
| Deferred revenue | $524 | $533 | $522 | |
| Short long term debt | $795 | $420 | ||
| Total current liabilities | $2389 | $1958 | $1617 | $1603 |
| Long term debt | $2137 | $2136 | $2555 | $2735 |
| Total noncurrent liabilities | $2704 | $2684 | $3143 | |
| Total debt | $2932 | $2556 | $2555 | |
| Total liabilities | $5093 | $4642 | $4760 | $4918 |
| Shareholders' equity | ||||
| Retained earnings | $773 | $1090 | $1061 | $782 |
| Other shareholder equity | -$331 | -$337 | -$316 | -$327 |
| Total shareholder equity | $5903 | $6214 | $6188 | |
| (in millions $) | 31 Jan 2024 | 1 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $1590 | $1053 | $1484 | $1441 |
| Short term investments | $91 | |||
| Net receivables | $1291 | $1405 | $1172 | $1038 |
| Inventory | $1031 | $1038 | $830 | $720 |
| Total current assets | $4186 | $3778 | $3799 | $3415 |
| Long term investments | $164 | $195 | $185 | $158 |
| Property, plant & equipment | $1270 | $1100 | $945 | $845 |
| Goodwill & intangible assets | $4435 | $4773 | $4956 | $4433 |
| Total noncurrent assets | $6577 | $6754 | $6906 | $6212 |
| Total investments | $164 | $195 | $276 | $158 |
| Total assets | $10763 | $10516 | $10705 | $9627 |
| Current liabilities | ||||
| Accounts payable | $418 | $580 | $446 | $354 |
| Deferred revenue | $505 | $461 | $441 | $386 |
| Short long term debt | $36 | $75 | ||
| Total current liabilities | $1603 | $1861 | $1708 | $1467 |
| Long term debt | $2735 | $2733 | $2729 | $2284 |
| Total noncurrent liabilities | $3315 | $3366 | $3608 | $3287 |
| Total debt | $2735 | $2769 | $2729 | $2359 |
| Total liabilities | $4918 | $5227 | $5316 | $4754 |
| Shareholders' equity | ||||
| Retained earnings | $782 | $324 | $348 | $81 |
| Other shareholder equity | -$327 | -$363 | -$282 | -$522 |
| Total shareholder equity | $5845 | $5305 | $5389 | $4873 |
| (in millions $) | 31 Aug 2024 | 30 May 2024 | 2 Mar 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1578 | $1573 | $1658 | |
| Cost of revenue | ||||
| Gross Profit | $855 | $856 | $908 | |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $522 | $493 | $524 | |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $61 | $66 | $55 | |
| Interest expense | -$3 | -$1 | -$4 | |
| Net income | ||||
| Net income | $282 | $308 | $348 | |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 1 Dec 2022 | 1 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $6848 | $5339 | ||
| Cost of revenue | $2502 | |||
| Gross Profit | $3722 | $2837 | ||
| Operating activities | ||||
| Research & development | $495 | |||
| Selling, general & administrative | $1496 | |||
| Total operating expenses | $2104 | $1991 | ||
| Operating income | $846 | |||
| Income from continuing operations | ||||
| EBIT | $920 | |||
| Income tax expense | $250 | $123 | ||
| Interest expense | -$75 | $78 | ||
| Net income | ||||
| Net income | $1254 | $719 | ||
| Income (for common shares) | $719 | |||
| (in millions $) | 31 Aug 2024 | 30 May 2024 | 2 Mar 2024 | 1 Dec 2023 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$304 | -$204 | -$95 | -$310 |
| Financing activities | ||||
| Dividends paid | -$206 | -$138 | -$69 | -$265 |
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$777 | -$531 | -$240 | -$930 |
| Effect of exchange rate | -$2 | $7 | $5 | |
| Change in cash and equivalents | $189 | $81 | $157 | $537 |
| (in millions $) | 31 Dec 2023 | 1 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $1240 | $1210 | $719 | |
| Operating activities | ||||
| Depreciation | $271 | $321 | $308 | |
| Business acquisitions & disposals | -$1 | -$546 | ||
| Stock-based compensation | $111 | $110 | $83 | |
| Total cash flows from operations | $1772 | $1485 | $921 | |
| Investing activities | ||||
| Capital expenditures | -$298 | -$187 | -$118 | |
| Investments | -$11 | -$15 | -$29 | |
| Total cash flows from investing | -$310 | -$338 | -$749 | -$147 |
| Financing activities | ||||
| Dividends paid | -$265 | -$250 | -$236 | -$222 |
| Sale and purchase of stock | -$508 | -$733 | -$409 | |
| Net borrowings | -$35 | $349 | -$49 | |
| Total cash flows from financing | -$930 | -$1372 | -$696 | -$717 |
| Effect of exchange rate | $5 | -$36 | $3 | $2 |
| Change in cash and equivalents | $537 | -$434 | $43 | $59 |
News
Fundamentals
| Market cap | $39.45B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 287.53M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | -5.62% |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.84 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.78 |
| Quick ratio | 1.37 |